Loading
companiesCompany
Nurix Therapeutics
Nurix Therapeutics is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for CLL, co-developed with Roche from June 2026.
Overview
Nurix Therapeutics, based in San Francisco and listed as NRIX, is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for chronic lymphocytic leukaemia, co-developed with Roche from June 2026. Bexobrutideg, or NX-5948, degrades both wild-type and inhibitor-resistant BTK and produced durable responses in relapsed or refractory CLL and small lymphocytic lymphoma, presented orally at EHA 2026; the 2026 plan includes the DAYBreak CLL-201 phase 2 and a confirmatory phase 3. OnCo links it to CLL and diffuse large B-cell lymphoma, to protein degradation and glue discovery platforms, to Roche, and to bottlenecks on acquired resistance and undruggable drivers. Whether a degrader can overcome the BTK mutations that defeat inhibitors in patients is the question its trials will answer. Roche has its own page.
Headquarters
San Francisco, CA, US
Scorecard
All companies#382of 1244 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Biotech · NRIX
Stage
Public
Website
Phase 3protein degrader
Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).
Similar pages
- CompanyKymera Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Use antibodies to deliver protein-destroying drugs into the right cells.
- CompanyC4 Therapeutics
Shares Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms, The undruggable drivers.
- CompanyMonte Rosa Therapeutics
Shares Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms, The undruggable drivers.
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Molecular glue discovery platforms, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation), Acquired resistance to every therapy.
- Key paperDrugging the 'undruggable' cancer targets
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it, Use antibodies to deliver protein-destroying drugs into the right cells, The undruggable drivers.
- TechnologyDegrader-antibody conjugate (DAC)
Shares Use antibodies to deliver protein-destroying drugs into the right cells, Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
- TreatmentBGB-16673
Shares PROTACs & molecular glues (targeted protein degradation), Acquired resistance to every therapy, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma.
- CompanyMersana Therapeutics
Shares Bain Capital Life Sciences, Acquired resistance to every therapy.
cancers
fronts
technologies
drugs
Phase 3protein degrader